SURPASS CVOT: Dr. Deepak Bhatt Breaks Down Tirzepatide CV Data скачать в хорошем качестве

SURPASS CVOT: Dr. Deepak Bhatt Breaks Down Tirzepatide CV Data

In SURPASS CVOT, a large cardiovascular outcomes trial enrolling more than 13,000 patients with type 2 diabetes and established atherosclerotic cardiovascular disease, tirzepatide demonstrated noninferiority to dulaglutide for the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke. As Deepak Bhatt, MD, explains, event rates numerically favored tirzepatide, with a trend toward superiority for ischemic outcomes and a nominally lower rate of all-cause mortality, alongside greater benefits in glycemic control and weight loss. While hierarchical testing precluded formal claims of superiority, Dr. Bhatt highlights that the totality of evidence—including efficacy, metabolic advantages, and comparable safety—positions tirzepatide as at least as effective as dulaglutide and potentially a preferred option for many patients with diabetes and cardiovascular disease.